Blueskyspecialtypharmacy

The company's business model is centered on coordinating between patients, physicians, payers, and pharmaceutical manufacturers. It serves clients by managing the prescription process, offering services like medication therapy management, adherence programs, and benefits investigation. Blue Sky generates revenue by facilitating access to and managing specialty prescriptions, a process supported by its multiple accreditations, including those from URAC and the Accreditation Commission for Health Care (ACHC) for infusion services. A significant milestone was achieved in September 2022 when the company secured a $10 million financing facility from CIT, a division of First Citizens Bank, to support its continued growth.

Blue Sky Specialty Pharmacy's core service is to streamline the acquisition of specialty drugs for patients with chronic and complex conditions like autoimmune disorders. Key features include a provider portal for efficient communication, a patient management program, and a "Patient Journey App" to help patients track their treatment and engage with their care team. The company also provides QR codes on prescription labels for easy access to medication information and training. A pivotal development occurred in June 2025 when Blue Sky transferred its specialty and a selection of injectable prescriptions to CVS Health. Following this transaction, the company has narrowed its focus to providing high-quality care for infusion patients, the bleeding disorder community, and those requiring immune globulin therapies.